JP2016530319A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016530319A5 JP2016530319A5 JP2016542105A JP2016542105A JP2016530319A5 JP 2016530319 A5 JP2016530319 A5 JP 2016530319A5 JP 2016542105 A JP2016542105 A JP 2016542105A JP 2016542105 A JP2016542105 A JP 2016542105A JP 2016530319 A5 JP2016530319 A5 JP 2016530319A5
- Authority
- JP
- Japan
- Prior art keywords
- liquid pharmaceutical
- pharmaceutical formulation
- viscosity
- proteins
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 claims description 55
- 239000008194 pharmaceutical composition Substances 0.000 claims description 46
- 238000009472 formulation Methods 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 34
- 108090000623 proteins and genes Proteins 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 229910019142 PO4 Inorganic materials 0.000 claims description 26
- 235000021317 phosphate Nutrition 0.000 claims description 26
- 239000007924 injection Substances 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 13
- 239000002904 solvent Substances 0.000 claims description 11
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 239000000872 buffer Substances 0.000 claims description 6
- 239000007927 intramuscular injection Substances 0.000 claims description 6
- 238000010255 intramuscular injection Methods 0.000 claims description 5
- 229940071643 prefilled syringe Drugs 0.000 claims description 5
- 238000010254 subcutaneous injection Methods 0.000 claims description 5
- 239000007929 subcutaneous injection Substances 0.000 claims description 5
- 150000005846 sugar alcohols Chemical class 0.000 claims description 5
- 229920005862 polyol Polymers 0.000 claims description 3
- 150000003077 polyols Chemical class 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 229940090047 auto-injector Drugs 0.000 claims description 2
- 239000004067 bulking agent Substances 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229920005615 natural polymer Polymers 0.000 claims description 2
- 229920001993 poloxamer 188 Polymers 0.000 claims description 2
- 229940044519 poloxamer 188 Drugs 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229950008882 polysorbate Drugs 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 239000001488 sodium phosphate Substances 0.000 claims description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 230000000638 stimulation Effects 0.000 claims description 2
- 229920001059 synthetic polymer Polymers 0.000 claims description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 9
- 238000007918 intramuscular administration Methods 0.000 claims 4
- 238000007920 subcutaneous administration Methods 0.000 claims 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 claims 2
- 239000006172 buffering agent Substances 0.000 claims 2
- 229960002363 thiamine pyrophosphate Drugs 0.000 claims 2
- 235000008170 thiamine pyrophosphate Nutrition 0.000 claims 2
- 239000011678 thiamine pyrophosphate Substances 0.000 claims 2
- YXVCLPJQTZXJLH-UHFFFAOYSA-N thiamine(1+) diphosphate chloride Chemical compound [Cl-].CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N YXVCLPJQTZXJLH-UHFFFAOYSA-N 0.000 claims 2
- 239000002577 cryoprotective agent Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 16
- 239000010452 phosphate Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 5
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 206010022079 Injection site irritation Diseases 0.000 description 1
- 108091006006 PEGylated Proteins Proteins 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 238000009295 crossflow filtration Methods 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Applications Claiming Priority (17)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361876621P | 2013-09-11 | 2013-09-11 | |
| US61/876,621 | 2013-09-11 | ||
| US201461940227P | 2014-02-14 | 2014-02-14 | |
| US61/940,227 | 2014-02-14 | ||
| US201461943197P | 2014-02-21 | 2014-02-21 | |
| US61/943,197 | 2014-02-21 | ||
| US201461946436P | 2014-02-28 | 2014-02-28 | |
| US61/946,436 | 2014-02-28 | ||
| US201461988005P | 2014-05-02 | 2014-05-02 | |
| US61/988,005 | 2014-05-02 | ||
| US201462008050P | 2014-06-05 | 2014-06-05 | |
| US62/008,050 | 2014-06-05 | ||
| US201462026497P | 2014-07-18 | 2014-07-18 | |
| US62/026,497 | 2014-07-18 | ||
| US201462030521P | 2014-07-29 | 2014-07-29 | |
| US62/030,521 | 2014-07-29 | ||
| PCT/US2014/055210 WO2015038782A1 (en) | 2013-09-11 | 2014-09-11 | Liquid protein formulations containing organophosphates |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018183794A Division JP6564512B2 (ja) | 2013-09-11 | 2018-09-28 | 有機ホスフェートを含有する液状タンパク質製剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016530319A JP2016530319A (ja) | 2016-09-29 |
| JP2016530319A5 true JP2016530319A5 (enExample) | 2017-10-05 |
| JP6412575B2 JP6412575B2 (ja) | 2018-10-24 |
Family
ID=51626611
Family Applications (12)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542105A Active JP6412575B2 (ja) | 2013-09-11 | 2014-09-11 | 有機ホスフェートを含有する液状タンパク質製剤 |
| JP2016542116A Active JP6515105B2 (ja) | 2013-09-11 | 2014-09-11 | イオン性液体を含有する注射用液状タンパク質製剤およびその使用 |
| JP2016542118A Active JP6463581B2 (ja) | 2013-09-11 | 2014-09-11 | 粘度低下剤を含む液状タンパク質製剤 |
| JP2016542103A Active JP6469113B2 (ja) | 2013-09-11 | 2014-09-11 | 水溶性有機色素を含有する液状タンパク質製剤 |
| JP2018183794A Active JP6564512B2 (ja) | 2013-09-11 | 2018-09-28 | 有機ホスフェートを含有する液状タンパク質製剤 |
| JP2018248768A Active JP6774484B2 (ja) | 2013-09-11 | 2018-12-29 | 粘度低下剤を含む液状タンパク質製剤 |
| JP2019031843A Active JP6768858B2 (ja) | 2013-09-11 | 2019-02-25 | イオン性液体を含有する液状タンパク質製剤 |
| JP2019108536A Active JP6941137B2 (ja) | 2013-09-11 | 2019-06-11 | イオン性液体を含有する液状タンパク質製剤 |
| JP2019137552A Active JP6840797B2 (ja) | 2013-09-11 | 2019-07-26 | 有機ホスフェートを含有する液状タンパク質製剤 |
| JP2020167521A Active JP7214697B2 (ja) | 2013-09-11 | 2020-10-02 | 粘度低下剤を含む液状タンパク質製剤 |
| JP2022200135A Active JP7583455B2 (ja) | 2013-09-11 | 2022-12-15 | 粘度低下剤を含む液状タンパク質製剤 |
| JP2024188410A Pending JP2025010224A (ja) | 2013-09-11 | 2024-10-25 | 粘度低下剤を含む液状タンパク質製剤 |
Family Applications After (11)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016542116A Active JP6515105B2 (ja) | 2013-09-11 | 2014-09-11 | イオン性液体を含有する注射用液状タンパク質製剤およびその使用 |
| JP2016542118A Active JP6463581B2 (ja) | 2013-09-11 | 2014-09-11 | 粘度低下剤を含む液状タンパク質製剤 |
| JP2016542103A Active JP6469113B2 (ja) | 2013-09-11 | 2014-09-11 | 水溶性有機色素を含有する液状タンパク質製剤 |
| JP2018183794A Active JP6564512B2 (ja) | 2013-09-11 | 2018-09-28 | 有機ホスフェートを含有する液状タンパク質製剤 |
| JP2018248768A Active JP6774484B2 (ja) | 2013-09-11 | 2018-12-29 | 粘度低下剤を含む液状タンパク質製剤 |
| JP2019031843A Active JP6768858B2 (ja) | 2013-09-11 | 2019-02-25 | イオン性液体を含有する液状タンパク質製剤 |
| JP2019108536A Active JP6941137B2 (ja) | 2013-09-11 | 2019-06-11 | イオン性液体を含有する液状タンパク質製剤 |
| JP2019137552A Active JP6840797B2 (ja) | 2013-09-11 | 2019-07-26 | 有機ホスフェートを含有する液状タンパク質製剤 |
| JP2020167521A Active JP7214697B2 (ja) | 2013-09-11 | 2020-10-02 | 粘度低下剤を含む液状タンパク質製剤 |
| JP2022200135A Active JP7583455B2 (ja) | 2013-09-11 | 2022-12-15 | 粘度低下剤を含む液状タンパク質製剤 |
| JP2024188410A Pending JP2025010224A (ja) | 2013-09-11 | 2024-10-25 | 粘度低下剤を含む液状タンパク質製剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (13) | US9913905B2 (enExample) |
| EP (8) | EP3043774B1 (enExample) |
| JP (12) | JP6412575B2 (enExample) |
| KR (5) | KR102289825B1 (enExample) |
| CN (7) | CN111202711B (enExample) |
| AU (10) | AU2014318691B2 (enExample) |
| CA (4) | CA2923844C (enExample) |
| ES (5) | ES2841134T3 (enExample) |
| HK (1) | HK1226309A1 (enExample) |
| IL (5) | IL312865B2 (enExample) |
| MX (6) | MX382917B (enExample) |
| RU (2) | RU2675824C2 (enExample) |
| SG (6) | SG10201809401XA (enExample) |
| SI (4) | SI3043774T1 (enExample) |
| WO (4) | WO2015038782A1 (enExample) |
| ZA (5) | ZA201601968B (enExample) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT2544719T (lt) | 2010-03-12 | 2019-10-25 | Debiopharm Int Sa | Cd37 surišančios molekulės, ir jų imunokonjugatai |
| AU2012236210B2 (en) | 2011-04-01 | 2016-02-04 | Immunogen, Inc. | CD37-binding molecules and immunoconjugates thereof |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| US20140348719A1 (en) * | 2013-03-14 | 2014-11-27 | Bureau Veritas | Pharmaceutical compound stabilizing filter compositions and methods of making and using same |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| ES2763429T5 (es) * | 2013-12-17 | 2023-06-21 | Hoffmann La Roche | Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos |
| US9499532B2 (en) | 2014-02-07 | 2016-11-22 | eXIthera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| WO2015196091A1 (en) * | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
| SG11201702614SA (en) | 2014-10-01 | 2017-04-27 | Eagle Biolog Inc | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| BR112017026027A2 (pt) * | 2015-06-08 | 2018-08-14 | Debiopharm Int Sa | combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20 |
| HRP20260689T1 (hr) | 2015-06-17 | 2026-07-17 | F. Hoffmann-La Roche Ag | Postupci za liječenje lokalno uznapredovalog ili metastatskog raka dojke primjenom antagonista vezivanja osi pd-1 i taksana |
| TW202440903A (zh) * | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| SI3769781T1 (sl) * | 2015-08-19 | 2023-06-30 | Astrazeneca Ab | Stabilna formulacija proti-IFNAR1 |
| JP6890581B2 (ja) | 2015-08-28 | 2021-06-18 | デビオファーム インターナショナル， エス． アー． | Ｃｄ３７の検出のための抗体およびアッセイ |
| WO2017049205A2 (en) * | 2015-09-18 | 2017-03-23 | Amunix Operating Inc. | Growth hormone formulation |
| WO2017055966A1 (en) * | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
| WO2017070501A1 (en) | 2015-10-23 | 2017-04-27 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| TW201730211A (zh) * | 2015-10-30 | 2017-09-01 | 建南德克公司 | 抗因子d抗體及結合物 |
| US20210206834A1 (en) * | 2015-12-03 | 2021-07-08 | Mor Research Applications Ltd. | Compositions and methods for treatment of ocular diseases |
| CA3010329A1 (en) * | 2015-12-29 | 2017-07-06 | Oncobiologics, Inc. | Buffered formulations of bevacizumab |
| CN105699555B (zh) * | 2016-03-24 | 2018-09-11 | 中国标准化研究院 | 一种丙烯基乙基愈创木酚的液相色谱制备方法 |
| JP2019514889A (ja) * | 2016-04-25 | 2019-06-06 | メディミューン，エルエルシー | 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物 |
| US20190192692A1 (en) * | 2016-05-05 | 2019-06-27 | The Trustees Of The University Of Pennsylvania | DNA Monoclonal Antibodies Targeting IL-6 and CD126 |
| WO2017214332A1 (en) * | 2016-06-07 | 2017-12-14 | National Technology & Engineering Solutions Of Sandia, Llc | Conversion of sugars to ionic liquids |
| EA201990316A1 (ru) * | 2016-08-18 | 2019-07-31 | Ридженерон Фармасьютикалз, Инк. | Анализ для определения потенциала самоассоциации белка с использованием концентрационно-зависимой спектроскопии самовзаимодействия на основе наночастиц |
| US11385201B1 (en) | 2019-09-30 | 2022-07-12 | United States Of America As Represented By The Secretary Of The Air Force | Ultra-stable protein ionic liquids |
| US11274137B1 (en) | 2016-10-04 | 2022-03-15 | United States Of America As Represented By The Secretary Of The Air Force | Ultra-stable protein ionic liquids |
| US11274163B1 (en) | 2016-10-04 | 2022-03-15 | United States Of America As Represented By The Secretary Of The Air Force | Ultra-stable protein ionic liquids |
| US10463733B1 (en) | 2016-10-04 | 2019-11-05 | United States of America as represented by the Secetary of the Air Force | Ultra-stable protein ionic liquids |
| US11274289B1 (en) | 2016-10-04 | 2022-03-15 | United States Of America As Represented By The Secretary Of The Air Force | Ultra-stable protein ionic liquids |
| US11382976B1 (en) | 2016-10-04 | 2022-07-12 | United States Of America As Represented By The Secretary Of The Air Force | Ultra-stable protein ionic liquids |
| KR102630042B1 (ko) * | 2016-10-27 | 2024-01-29 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 알츠하이머병의 치료를 위한 항-a베타 원시섬유 항체 및 베타-세크레타제 bace1 억제제를 포함하는 조성물 |
| US11278629B2 (en) | 2016-11-02 | 2022-03-22 | Debiopharm International, S.A. | Methods for improving anti-CD37 immunoconjugate therapy |
| EP3534963B1 (en) * | 2016-11-02 | 2024-04-17 | Polaris Group | Formulations of pegylated arginine deiminase |
| CA3053909A1 (en) * | 2017-02-16 | 2018-08-23 | Reform Biologics, Llc | Excipient compounds for protein processing |
| JOP20190204A1 (ar) * | 2017-03-08 | 2019-09-05 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على سيليكسيباغ |
| US10238600B2 (en) | 2017-04-13 | 2019-03-26 | Richard C. Fuisz | Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent |
| US9901545B1 (en) | 2017-04-13 | 2018-02-27 | Richard C. Fuisz | Method and composition for making an oral soluble film, containing at least one active agent |
| BR112019021723A2 (pt) * | 2017-04-18 | 2021-06-29 | Dr. Reddy's Laboratories Limited | formulação de anticorpo líquida estável, anticorpo na formulação, formulação líquida estável de anticorpo anti-il6r, formulação líquida estável de tocilizumab em sistema de tampão de fosfato-aminoácido, e, formulação líquida estável de tocilizumab |
| MA48461A (fr) * | 2017-04-28 | 2020-03-04 | Amgen Inc | Excipients pour réduire la viscosité de formulations d'anticorps et compositions de formulation |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| CN110913906A (zh) | 2017-05-02 | 2020-03-24 | 默沙东公司 | 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂 |
| US10646569B2 (en) | 2017-05-16 | 2020-05-12 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
| EP3646887A4 (en) * | 2017-06-30 | 2021-03-24 | Korea Advanced Institute of Science and Technology | CONJUGATE OF VEGF GRAB PROTEIN AND MEDICINAL PRODUCTS AND USES THEREOF |
| US20210363259A1 (en) * | 2017-08-22 | 2021-11-25 | Biogen Ma Inc. | Pharmaceutical compositions and dosage regimens containing anti-alpha(v)beta(6) antibodies |
| EP3678700B1 (en) * | 2017-09-05 | 2024-06-19 | Merck Sharp & Dohme LLC | Compounds for reducing the viscosity of biological formulations |
| US20200261549A1 (en) * | 2017-11-07 | 2020-08-20 | Alphacore Pharma Llc | Methods of treating and protecting against cardiac disease, cardiovascular disease and related conditions and symptoms |
| WO2019099837A1 (en) * | 2017-11-17 | 2019-05-23 | President And Fellows Of Harvard College | Ionic liquids for internal delivery |
| CN108096185A (zh) * | 2017-12-20 | 2018-06-01 | 珠海冀百康生物科技有限公司 | 一种速效胰岛素制剂及其制备方法 |
| JP7256816B2 (ja) * | 2018-03-07 | 2023-04-12 | コメラ ライフ サイエンシズ，インコーポレイテッド | タンパク質製剤用の賦形剤化合物 |
| AU2019254483B2 (en) * | 2018-04-16 | 2025-02-27 | Merck Patent Gmbh | Viscosity reduction of highly concentrated protein formulations |
| CN108671229B (zh) * | 2018-05-08 | 2022-03-25 | 华博生物医药技术（上海）有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
| AU2019277836A1 (en) | 2018-05-30 | 2021-01-21 | Debiopharm International, S.A. | Anti-CD37 immunoconjugate dosing regimens |
| EP3824904A4 (en) * | 2018-07-19 | 2021-08-25 | Celltrion, Inc. | STABLE LIQUID PHARMACEUTICAL PREPARATION |
| MX2021004356A (es) | 2018-10-18 | 2021-05-31 | Merck Sharp & Dohme Llc | Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas. |
| CA3113560A1 (en) * | 2018-10-19 | 2020-04-23 | F. Hoffmann-La Roche Ag | Microdosing |
| MA54089A (fr) | 2018-10-31 | 2022-02-09 | Merck Sharp & Dohme | Anticorps anti-pd-1 humain et procédés d'utilisation associés |
| JP7503056B6 (ja) | 2018-11-07 | 2024-07-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体および抗ｐｄ－１抗体の共－製剤 |
| EA202191403A1 (ru) * | 2018-11-21 | 2021-08-09 | Ридженерон Фармасьютикалз, Инк. | Композиция с высокой концентрацией белка |
| US11058770B1 (en) * | 2019-01-24 | 2021-07-13 | United States Of America As Represented By The Secretary Of The Air Force | Ultrastable antibody ionic liquids |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| WO2020180534A1 (en) | 2019-03-01 | 2020-09-10 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
| US20220220196A1 (en) * | 2019-04-24 | 2022-07-14 | Janssen Biotech, Inc. | Antibody formulation |
| EP3771463A1 (en) | 2019-07-29 | 2021-02-03 | Ludwig-Maximilians-Universität München | Stabilizing therapeutic proteins with piperazin- or morpholine-containing zwitterionic buffering substances |
| AU2020347827A1 (en) * | 2019-09-17 | 2022-05-05 | Merck Patent Gmbh | Camphorsulfonic acid and combinations thereof with cationic excipients as viscosity reducing agents in high concentrated protein formulations |
| US11684594B2 (en) | 2020-05-12 | 2023-06-27 | President And Fellows Of Harvard College | Antifungal prophylaxis for cornea |
| WO2022178279A1 (en) | 2021-02-19 | 2022-08-25 | Nova Thin Film Pharmaceuticals Llc | Method and system for manufacturing oral soluble films, compositions of oral soluble films, oral soluble films made by thereby, and methods of use thereof |
| CA3187322A1 (en) * | 2020-07-13 | 2022-01-20 | Merck Patent Gmbh | Viscosity reducing excipients and combinations thereof for highly concentrated protein formulations |
| MX2023002510A (es) * | 2020-09-01 | 2023-05-17 | I2O Therapeutics Inc | Formulaciones liquidas ionicas para el tratamiento de diabetes. |
| US20240123067A1 (en) * | 2020-12-17 | 2024-04-18 | Iovance Biotherapeutics, Inc. | Treatment of cancers with tumor infiltrating lymphocyte therapies |
| CN113249358B (zh) * | 2021-05-14 | 2022-10-14 | 天津大学 | 一种利用离子液体调控溶菌酶晶型的方法 |
| FI4185318T3 (fi) | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
| US20240277840A1 (en) * | 2021-07-01 | 2024-08-22 | Upkara, Inc. | Superconcentrated formulations of bioactive agents |
| WO2023025437A1 (de) * | 2021-08-25 | 2023-03-02 | Guido Knobel | Vorrichtung zum herstellen eines pharmazeutikums, nahrungsergänzungsmittel oder kosmetikums |
| CA3237751A1 (en) | 2021-11-10 | 2023-05-19 | Tyler Brown | Ionic liquid compositions |
| CN115350330B (zh) * | 2022-09-01 | 2023-10-20 | 北京化工大学 | 一种负电性小分子调控的表面在蛋白差异性黏附上的应用 |
| WO2024189048A1 (en) | 2023-03-13 | 2024-09-19 | Heidelberg Pharma Research Gmbh | Subcutaneously administered antibody-drug conjugates for use in cancer treatment |
| WO2026006472A2 (en) | 2024-06-25 | 2026-01-02 | Kiniksa Pharmaceuticals, Gmbh | Compositions of il-1r1 antibodies and methods of producing and using the same |
| WO2026003765A1 (en) | 2024-06-25 | 2026-01-02 | Kiniksa Pharmaceuticals, Gmbh | Formulations of anti-interleukin 1 receptor 1 antibodies |
Family Cites Families (186)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US190082A (en) | 1877-04-24 | Improvement in apparatus for cooling liquids | ||
| GB750373A (en) | 1953-01-15 | 1956-06-13 | Pfizer & Co C | Improvements in or relating to injectable suspension of penicillin salts |
| DK128416B (da) | 1964-08-13 | 1974-04-29 | Ciba Geigy Ag | Analogifremgangsmåde til fremstilling af adrenocorticotropt aktive nonadecapeptidamider eller syreadditionssalte eller kompleksforbindelser deraf. |
| BE757195A (fr) | 1969-10-07 | 1971-03-16 | Century Disposable Devices | Seringue servant a injecter un melange fraichement prepare de poudre etde liquide |
| JPS5270014A (en) | 1975-12-05 | 1977-06-10 | Senju Pharma Co | Stabilization of pyrido*3*22a*phenoxadine compounds |
| US4171698A (en) | 1977-08-15 | 1979-10-23 | Abbott Laboratories | Prefilled two-compartment syringe |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5521063A (en) | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
| US5506337A (en) | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
| JP2528107B2 (ja) | 1985-03-15 | 1996-08-28 | サマ−トン，ジエ−ムス | ポリヌクレオチド測定試薬と方法 |
| US5217866A (en) | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
| US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
| AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
| US5001000A (en) | 1988-09-26 | 1991-03-19 | E. I. Du Pont De Nemours And Company | Process for forming a composite structure of thermoplastic polymer and sheet molding compound |
| US5114703A (en) | 1989-05-30 | 1992-05-19 | Alliance Pharmaceutical Corp. | Percutaneous lymphography using particulate fluorocarbon emulsions |
| US5730978A (en) | 1989-09-01 | 1998-03-24 | Fred Hutchinson Cancer Research Center | Inhibition of lymphocyte adherence with α4β1-specific antibodies |
| US6033665A (en) | 1989-09-27 | 2000-03-07 | Elan Pharmaceuticals, Inc. | Compositions and methods for modulating leukocyte adhesion to brain endothelial cells |
| JPH03190823A (ja) * | 1989-12-21 | 1991-08-20 | Snow Brand Milk Prod Co Ltd | エリスロポエチン皮下又は筋肉投与剤 |
| US5698195A (en) | 1991-03-18 | 1997-12-16 | New York University Medical Center | Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies |
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
| US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
| US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| SG44845A1 (en) | 1993-01-12 | 1997-12-19 | Biogen Inc | Recombitant anti-vla4 antibody molecules |
| US5334162A (en) | 1993-03-15 | 1994-08-02 | Eli Lilly And Company | Cartridge assembly for a lyophilized compound forming a disposable portion of an injector pen and method for same |
| US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
| US5527675A (en) | 1993-08-20 | 1996-06-18 | Millipore Corporation | Method for degradation and sequencing of polymers which sequentially eliminate terminal residues |
| DE4331012A1 (de) | 1993-09-13 | 1995-03-16 | Bayer Ag | Nukleinsäuren-bindende Oligomere mit N-Verzweigung für Therapie und Diagnostik |
| DE4344824C1 (de) | 1993-12-28 | 1995-08-31 | Immuno Ag | Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| GB9418092D0 (en) | 1994-09-08 | 1994-10-26 | Red Cross Found Cent Lab Blood | Organic compounds |
| JP3524974B2 (ja) | 1994-12-26 | 2004-05-10 | ブラッコ インターナショナル ビーヴィ | プレフィルドシリンジおよびその包装体 |
| US5569193A (en) | 1995-03-22 | 1996-10-29 | Abbott Laboratories | Syringe system accommodating separately storable prefilled containers for two constituents |
| US5779668A (en) | 1995-03-29 | 1998-07-14 | Abbott Laboratories | Syringe barrel for lyophilization, reconstitution and administration |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| DE19617369A1 (de) | 1996-04-30 | 1997-11-06 | Immuno Ag | Lagerstabile Fibrinogen-Präparate |
| US6184037B1 (en) | 1996-05-17 | 2001-02-06 | Genemedicine, Inc. | Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell |
| GB9610992D0 (en) * | 1996-05-24 | 1996-07-31 | Glaxo Group Ltd | Concentrated antibody preparation |
| US5819998A (en) | 1996-09-30 | 1998-10-13 | Everything Kids | Knapsack with simulated basketball court |
| IN184589B (enExample) | 1996-10-16 | 2000-09-09 | Alza Corp | |
| US5819988A (en) | 1997-04-01 | 1998-10-13 | Sawhney; Ravi K. | Double-barreled syringe with detachable locking mixing tip |
| US6065645A (en) | 1997-04-01 | 2000-05-23 | Discus Dental Impressions, Inc. | Double-barreled syringe with detachable locking mixing tip |
| US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US5786571A (en) | 1997-05-09 | 1998-07-28 | Lexmark International, Inc. | Wrapped temperature sensing assembly |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| WO1999018994A1 (en) * | 1997-10-15 | 1999-04-22 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for keeping the quality of aqueous parenteral solution of thrombomodulin in storage and distribution |
| DE69837399T2 (de) | 1997-10-22 | 2007-12-20 | Chugai Seiyaku K.K. | Verfahren zum screening von tgf-beta inhibierenden substanzen |
| US6572856B1 (en) * | 1998-09-10 | 2003-06-03 | The University Of Virginia Patent Foundation | Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies |
| US7919109B2 (en) | 1999-02-08 | 2011-04-05 | Intarcia Therapeutics, Inc. | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
| US6372494B1 (en) * | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
| FR2794649B1 (fr) | 1999-06-11 | 2003-04-11 | Solutions | Biomateriau a base d'un derive de dextrane insolubilise et d'un facteur de croissance, son procede de preparation et ses applications |
| AUPQ132599A0 (en) | 1999-07-01 | 1999-07-22 | Commonwealth Scientific And Industrial Research Organisation | Nasogastric enteral formulations |
| US7030097B1 (en) | 1999-07-14 | 2006-04-18 | Cornell Research Foundation, Inc. | Controlled nucleic acid delivery systems |
| EP1072323B1 (de) | 1999-07-29 | 2003-09-10 | Wilhelm A. Keller | Kartuschen-Austraggerät mit Antrieb für dynamischen Mischer |
| CZ305123B6 (cs) | 1999-10-04 | 2015-05-13 | Novartis Vaccines And Diagnostics, Inc. | Způsob výroby kapalného farmaceutického prostředku |
| US6394314B1 (en) | 1999-10-12 | 2002-05-28 | Discus Dental Impressions, Inc. | Double-barreled syringe with detachable locking mixing tip |
| US6443612B1 (en) | 1999-12-02 | 2002-09-03 | Wilhelm A. Keller | Dynamic mixer |
| DE60139944D1 (de) | 2000-10-12 | 2009-10-29 | Genentech Inc | Niederviskose konzentrierte proteinformulierungen |
| US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
| JP4434583B2 (ja) | 2000-11-30 | 2010-03-17 | バイオバルブ テクノロジーズ インコーポレイテッド | 注射システム |
| CN100523215C (zh) | 2000-12-01 | 2009-08-05 | 马普科技促进协会 | 介导rna干涉的小rna分子 |
| CA2446127A1 (en) | 2001-05-16 | 2002-11-21 | Biomarin Pharmaceutical Inc. | Destruction of prions using vibriolysin or variants thereof |
| GB0113179D0 (en) | 2001-05-31 | 2001-07-25 | Novartis Ag | Organic compounds |
| US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
| ATE454137T1 (de) | 2001-07-25 | 2010-01-15 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
| BR0211579A (pt) | 2001-08-02 | 2004-07-13 | 3M Innovative Properties Co | Vidro-cerâmica, contas, pluralidade de partìculas abrasivas, artigo abrasivo, e, métodos para abradar uma superfìcie, para fabricar vidro-cerâmica, para fabricar um artigo de vidro-cerâmica e para fabricar partìculas abrasivas |
| JP4167820B2 (ja) * | 2001-10-19 | 2008-10-22 | アルインコ株式会社 | デッキプレート走行台車 |
| GB0212405D0 (en) | 2002-05-29 | 2002-07-10 | Insignion Holdings Ltd | Composition and its therapeutic use |
| WO2004012703A1 (en) * | 2002-07-31 | 2004-02-12 | Alza Corporation | Injectable depot compositions and uses thereof |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
| EP2330213A1 (en) | 2003-03-05 | 2011-06-08 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| RU2005133427A (ru) | 2003-03-31 | 2006-04-27 | Алза Корпорейшн (Us) | Безводные однофазные носители и препараты с использованием таких носителей |
| US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
| PT1610820E (pt) | 2003-04-04 | 2010-12-16 | Novartis Ag | Formulações de elevada concentração de anticorpos e proteínas |
| US7341843B2 (en) | 2003-04-11 | 2008-03-11 | Allergan, Inc. | Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
| AU2004230482A1 (en) | 2003-04-15 | 2004-10-28 | Biozyme Laboratories, Ltd | Process for isolating and purifing ovine hyaluronidase |
| US20040247672A1 (en) | 2003-05-16 | 2004-12-09 | Alkermes Controlled Therapeutics, Inc. | Injectable sustained release compositions |
| US20070184084A1 (en) | 2003-05-30 | 2007-08-09 | Guohua Chen | Implantable elastomeric caprolactone depot compositions and uses thereof |
| JP5275566B2 (ja) | 2003-06-18 | 2013-08-28 | ザ スクリプス リサーチ インスティチュート | 反応性非天然アミノ酸遺伝コード付加 |
| MXPA05014171A (es) | 2003-06-23 | 2007-02-21 | Sanofi Pasteur Inc | Metodo de inmunizacion contra neisseria meningitidis serogrupos a y c. |
| CN1206344C (zh) | 2003-07-28 | 2005-06-15 | 中国海洋大学 | 一种用细菌生产岩藻聚糖硫酸酯酶的方法 |
| GB0327723D0 (en) | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| AU2004317954A1 (en) * | 2003-09-17 | 2005-10-13 | Chiasma, Inc. | Compositions capable of facilitating penetration across a biological barrier |
| EP1532983A1 (en) | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
| GB0403938D0 (en) | 2004-02-21 | 2004-03-24 | West Pharm Serv Drug Res Ltd | Chitosan containing solution |
| ES2643237T3 (es) | 2004-06-21 | 2017-11-21 | E. R. Squibb & Sons, L.L.C. | Anticuerpos del receptor 1 de interferón alfa y sus usos |
| DE602004027396D1 (de) | 2004-11-25 | 2010-07-08 | Chr Hansen As | Verfahren zur Herstellung eines Karminsaürelackes |
| US20060141040A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| US20060142234A1 (en) | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
| PA8661401A1 (es) * | 2005-01-28 | 2006-09-08 | Wyeth Corp | Formulaciones del liquido polipeptido estabilizado |
| JP5713534B2 (ja) | 2005-10-07 | 2015-05-07 | ザ ユニバーシティ オブ アラバマ | 多機能イオン性液体組成物 |
| CN100416002C (zh) * | 2005-10-26 | 2008-09-03 | 曲新华 | 污水再生利用装置 |
| US9309316B2 (en) | 2005-12-20 | 2016-04-12 | Bristol-Myers Squibb Company | Stable subcutaneous protein formulations and uses thereof |
| TW200738261A (en) | 2005-12-20 | 2007-10-16 | Bristol Myers Squibb Co | Stable protein formulations |
| JP5405122B2 (ja) | 2005-12-21 | 2014-02-05 | ワイス・エルエルシー | 低粘度のタンパク質製剤およびその用途 |
| JP5231810B2 (ja) | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| CN1823768A (zh) * | 2006-01-09 | 2006-08-30 | 徐新盛 | 西咪替丁冻干组合物 |
| JP2009525986A (ja) | 2006-02-03 | 2009-07-16 | メディミューン，エルエルシー | タンパク質製剤 |
| DE102006005094A1 (de) | 2006-02-04 | 2007-08-09 | Degussa Gmbh | Titandioxid und Polycarboxylatether enthaltende Dispersion |
| ITMI20061030A1 (it) | 2006-05-26 | 2007-11-27 | Altergon Sa | Nuova composizione comprendente glicosamminoglicani a viscosita' controllata e uso di tale composizione nella terapuia della cistite cronica |
| CU23526B6 (es) | 2006-10-03 | 2010-05-19 | Ct Ingenieria Genetica Biotech | Método para la restauración morfofuncional de nervios periféricos en la neuropatía diabética |
| WO2008092084A2 (en) | 2007-01-26 | 2008-07-31 | Centocor, Inc. | Injectable non-aqueous suspension with high concentration of therapeutic agent |
| WO2008151022A2 (en) | 2007-05-31 | 2008-12-11 | Anterios, Inc. | Nucleic acid nanoparticles and uses therefor |
| KR101502305B1 (ko) | 2007-07-20 | 2015-03-13 | 어플라이드 머티어리얼스, 인코포레이티드 | 플라즈마 처리 장치 내의 ｒｆ 구동된 전극으로 가스를 전달하기 위한 ｒｆ 초크 |
| WO2009015367A2 (en) | 2007-07-25 | 2009-01-29 | Arizona Board Of Regents For And On Behalf Of Arizona State University | Stabilizing proteins using ionic liquids |
| WO2009026122A1 (en) | 2007-08-17 | 2009-02-26 | Amgen Inc. | Formulations of antibodies and fc-fusion molecules using polycations |
| AU2008304111B2 (en) | 2007-09-27 | 2014-04-24 | Amgen Inc. | Pharmaceutical formulations |
| CN103705507A (zh) | 2007-10-16 | 2014-04-09 | 环状药物公司 | 凝血因子viia调节剂的制造、组合物和用途 |
| US8796206B2 (en) | 2007-11-15 | 2014-08-05 | Amgen Inc. | Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration |
| US8420081B2 (en) * | 2007-11-30 | 2013-04-16 | Abbvie, Inc. | Antibody formulations and methods of making same |
| US8858927B2 (en) | 2007-12-21 | 2014-10-14 | Lyotropic Therapeutics, Inc. | Method for protection of peptides or proteins against non-enzymatic deamidation |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| US20120251615A1 (en) * | 2008-01-18 | 2012-10-04 | Horst Kief | Agent for intra-articular injection |
| WO2009120684A1 (en) * | 2008-03-25 | 2009-10-01 | Medimmune, Llc | Antibody formulation |
| WO2009137471A2 (en) * | 2008-05-05 | 2009-11-12 | University Of Miami | Azo dye related small molecule modulators of protein-protein interactions |
| EP2123307A1 (en) * | 2008-05-20 | 2009-11-25 | Hexal Ag | Method for reducing leachables and extractables in syringes |
| US8779094B2 (en) | 2008-11-16 | 2014-07-15 | Board Of Regents, The University Of Texas System | Low viscosity highly concentrated suspensions |
| TWI342781B (en) | 2008-12-01 | 2011-06-01 | Univ China Medical | Blood sugar-modulating polypeptides |
| PE20120359A1 (es) | 2009-03-06 | 2012-04-13 | Genentech Inc | Formulacion con anticuerpo |
| US20100278822A1 (en) | 2009-05-04 | 2010-11-04 | Abbott Biotechnology, Ltd. | Stable high protein concentration formulations of human anti-tnf-alpha-antibodies |
| WO2010132047A1 (en) | 2009-05-14 | 2010-11-18 | Rensselaer Polytechnic Institute | Guanosine/gmp gels and uses thereof |
| CA2762611C (en) | 2009-05-20 | 2017-03-28 | Sekisui Medical Co., Ltd. | Blood coagulation time prolonging agent |
| US8785168B2 (en) | 2009-06-17 | 2014-07-22 | Biomarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
| WO2011017070A1 (en) * | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| WO2011017330A1 (en) * | 2009-08-04 | 2011-02-10 | Genentech Inc | Concentrated polypeptide formulations with reduced viscosity |
| AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| PT2477603E (pt) | 2009-09-17 | 2016-06-16 | Baxalta Inc | Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização |
| WO2011050000A2 (en) | 2009-10-20 | 2011-04-28 | The Regents Of The University Of California | Single molecule nucleic acid nanoparticles |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| PL3721904T3 (pl) | 2009-11-20 | 2022-01-31 | Biocon Limited | Formulacje przeciwciała t1h |
| US9289381B2 (en) * | 2009-12-03 | 2016-03-22 | The University Of North Carolina At Charlotte | Stabilization and storage of biological pharmaceutical compositions |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| JP5746214B2 (ja) | 2010-01-08 | 2015-07-08 | シャネル パフュームズ ビューテ | 皮膚に潤いを与えるための、ヤブツバキアルバプレナ（ＣａｍｅｌｌｉａＪａｐｏｎｉｃａＡｌｂａＰｌｅｎａ）の花の少なくとも１つの抽出物の使用 |
| DK2531218T3 (en) | 2010-02-04 | 2019-04-01 | Csl Behring Ag | immunoglobulin |
| SI3409289T1 (sl) | 2010-02-26 | 2020-12-31 | Novo Nordisk A/S | Stabilni sestavki, ki vsebujejo protitelo |
| SG184355A1 (en) | 2010-03-01 | 2012-11-29 | Progenics Pharm Inc | Concentrated protein formulations and uses thereof |
| US20130171128A1 (en) | 2010-03-02 | 2013-07-04 | Amgen Inc. | Reducing viscosity of pharmaceutical formulations |
| US20110223208A1 (en) * | 2010-03-09 | 2011-09-15 | Beth Hill | Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| US9072668B2 (en) | 2010-03-09 | 2015-07-07 | Janssen Biotech, Inc. | Non-aqueous high concentration reduced viscosity suspension formulations of antibodies |
| KR20130031247A (ko) * | 2010-03-17 | 2013-03-28 | 애보트 리서치 비.브이. | 항―신경 성장 인자（ｎｇｆ） 항체 조성물 |
| WO2011121560A2 (en) * | 2010-03-31 | 2011-10-06 | Universite De Geneve | Stabilized antibody preparations and uses thereof |
| CN101851267A (zh) | 2010-04-22 | 2010-10-06 | 江南大学 | 一种抗体保护剂及其应用 |
| BR112012027828A2 (pt) | 2010-05-03 | 2016-08-09 | Genentech Inc | composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína |
| SMT202000095T1 (it) * | 2010-05-14 | 2020-03-13 | Amgen Inc | Formulazioni di anticorpi anti-sclerostina ad alta concentrazione |
| GB201012179D0 (en) | 2010-07-20 | 2010-09-01 | Future Injection Technologies | Injection device |
| JP6014596B2 (ja) * | 2010-11-09 | 2016-10-25 | メディミューン，エルエルシー | 均一コンジュゲーションのための抗体足場 |
| TWI603739B (zh) * | 2010-11-11 | 2017-11-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗－ＴＮＦα抗體之液體調配物 |
| US8936827B2 (en) | 2011-02-25 | 2015-01-20 | Abbott Cardiovascular Systems Inc. | Methods of loading a hollow stent with a drug or drug formulation |
| BR112013025845A2 (pt) | 2011-04-07 | 2018-09-04 | Glaxosmithkline Llc | formulações com viscosidade reduzida |
| BR112013025866A2 (pt) | 2011-04-07 | 2016-12-20 | Glaxosmithkline Llc | formulações com viscosidade reduzida |
| AU2012253387B2 (en) | 2011-05-12 | 2016-05-19 | Bayer Healthcare Llc | Fluid injection system having various systems for controlling an injection procedure |
| RU2485133C2 (ru) | 2011-05-30 | 2013-06-20 | Закрытое Акционерное Общество "Фарм-Синтез" | Белково-полипептидный комплекс, обладающий тканеспецифическим регенеративно-репаративным и омолаживающим действием на кожную ткань, способ его получения и фармацевтическая композиция на его основе |
| CN102349895B (zh) * | 2011-09-28 | 2013-04-10 | 海南良方医药有限公司 | 一种注射用西咪替丁组合物及其制备方法 |
| US9186295B2 (en) | 2011-10-25 | 2015-11-17 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| AU2012328524B2 (en) | 2011-10-28 | 2017-05-18 | Excelse Bio, Inc. | Protein formulations containing amino acids |
| WO2013096835A1 (en) * | 2011-12-23 | 2013-06-27 | Abbvie Inc. | Stable protein formulations |
| AR089434A1 (es) | 2011-12-23 | 2014-08-20 | Genentech Inc | Procedimiento para preparar formulaciones con alta concentracion de proteinas |
| US20140370012A1 (en) * | 2012-01-27 | 2014-12-18 | Gliknik Inc. | Fusion proteins comprising igg2 hinge domains |
| WO2013123114A2 (en) | 2012-02-16 | 2013-08-22 | Santarus, Inc. | Antibody formulations |
| US20160002624A1 (en) | 2012-05-17 | 2016-01-07 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
| US9574193B2 (en) | 2012-05-17 | 2017-02-21 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein (a) expression |
| SI2849723T1 (sl) | 2012-05-18 | 2018-09-28 | Genentech, Inc. | Formulacije z visoko koncentracijo monoklonskih protiteles |
| CA2866232A1 (en) | 2012-05-25 | 2013-11-28 | Novartis Ag | Aqueous pharmaceutical composition containing a biologic therapeutic agent and guanidine or a guanidine derivative and an injection including the composition |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| CN104520326A (zh) | 2012-06-21 | 2015-04-15 | Ucb医药有限公司 | 药物制剂 |
| CN116622704A (zh) | 2012-07-25 | 2023-08-22 | 布罗德研究所有限公司 | 可诱导的dna结合蛋白和基因组干扰工具及其应用 |
| WO2014023709A1 (en) | 2012-08-09 | 2014-02-13 | Roche Glycart Ag | Asgpr antibodies and uses thereof |
| FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
| US9592297B2 (en) | 2012-08-31 | 2017-03-14 | Bayer Healthcare Llc | Antibody and protein formulations |
| FR2995214B1 (fr) | 2012-09-10 | 2014-11-21 | Adocia | Solution a viscosite reduite de proteine a concentration elevee |
| EP2968873A4 (en) | 2013-03-13 | 2016-10-26 | Applied Cardiovascular Solutions Llc | METHODS, COMPOSITIONS AND DEVICES FOR THE OCCLUSION OF CAVITIES AND PASSAGES |
| US9669242B2 (en) | 2013-07-01 | 2017-06-06 | L'oreal | Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use |
| IL312865B2 (en) | 2013-09-11 | 2025-06-01 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
| WO2015196091A1 (en) | 2014-06-20 | 2015-12-23 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
| SG11201702614SA (en) * | 2014-10-01 | 2017-04-27 | Eagle Biolog Inc | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
| US10812184B1 (en) | 2019-04-03 | 2020-10-20 | Board Of Trustees Of The University Of Alabama, For And On Behalf Of The University Of Alabama In Huntsville | Signal analysis systems and methods |
-
2014
- 2014-09-10 IL IL312865A patent/IL312865B2/en unknown
- 2014-09-11 KR KR1020167009551A patent/KR102289825B1/ko active Active
- 2014-09-11 SI SI201431701T patent/SI3043774T1/sl unknown
- 2014-09-11 CN CN202010059409.6A patent/CN111202711B/zh active Active
- 2014-09-11 ES ES14776953T patent/ES2841134T3/es active Active
- 2014-09-11 RU RU2016113385A patent/RU2675824C2/ru active
- 2014-09-11 MX MX2016003182A patent/MX382917B/es unknown
- 2014-09-11 EP EP14776953.3A patent/EP3043774B1/en active Active
- 2014-09-11 JP JP2016542105A patent/JP6412575B2/ja active Active
- 2014-09-11 EP EP14776954.1A patent/EP3043775B1/en active Active
- 2014-09-11 SG SG10201809401XA patent/SG10201809401XA/en unknown
- 2014-09-11 EP EP23183441.7A patent/EP4272763A3/en not_active Withdrawn
- 2014-09-11 ES ES20205250T patent/ES2980815T3/es active Active
- 2014-09-11 KR KR1020227028657A patent/KR102651018B1/ko active Active
- 2014-09-11 EP EP14781337.2A patent/EP3043776B1/en active Active
- 2014-09-11 AU AU2014318691A patent/AU2014318691B2/en active Active
- 2014-09-11 AU AU2014318637A patent/AU2014318637B2/en active Active
- 2014-09-11 US US14/483,896 patent/US9913905B2/en active Active
- 2014-09-11 WO PCT/US2014/055210 patent/WO2015038782A1/en not_active Ceased
- 2014-09-11 EP EP24178356.2A patent/EP4403187A3/en not_active Withdrawn
- 2014-09-11 IL IL318339A patent/IL318339A/en unknown
- 2014-09-11 KR KR1020217026965A patent/KR102435648B1/ko active Active
- 2014-09-11 CA CA2923844A patent/CA2923844C/en active Active
- 2014-09-11 IL IL275388A patent/IL275388B2/en unknown
- 2014-09-11 EP EP20199033.0A patent/EP3808338A1/en not_active Withdrawn
- 2014-09-11 MX MX2016003183A patent/MX386756B/es unknown
- 2014-09-11 HK HK16114708.6A patent/HK1226309A1/zh unknown
- 2014-09-11 CN CN201480061378.0A patent/CN105848636B/zh active Active
- 2014-09-11 SI SI201431702T patent/SI3043775T1/sl unknown
- 2014-09-11 US US14/483,880 patent/US10179172B2/en active Active
- 2014-09-11 CA CA2924069A patent/CA2924069C/en active Active
- 2014-09-11 CN CN201910735461.6A patent/CN110559435B/zh active Active
- 2014-09-11 EP EP14781338.0A patent/EP3043772B1/en active Active
- 2014-09-11 WO PCT/US2014/055245 patent/WO2015038811A2/en not_active Ceased
- 2014-09-11 JP JP2016542116A patent/JP6515105B2/ja active Active
- 2014-09-11 JP JP2016542118A patent/JP6463581B2/ja active Active
- 2014-09-11 ES ES14781337T patent/ES2972527T3/es active Active
- 2014-09-11 SI SI201432065T patent/SI3043776T1/sl unknown
- 2014-09-11 AU AU2014318696A patent/AU2014318696B2/en active Active
- 2014-09-11 SI SI201432039T patent/SI3043772T1/sl unknown
- 2014-09-11 SG SG10201913952TA patent/SG10201913952TA/en unknown
- 2014-09-11 KR KR1020167009556A patent/KR102295633B1/ko active Active
- 2014-09-11 RU RU2016113283A patent/RU2710542C2/ru active
- 2014-09-11 US US14/484,053 patent/US9833513B2/en active Active
- 2014-09-11 SG SG10201913950XA patent/SG10201913950XA/en unknown
- 2014-09-11 WO PCT/US2014/055203 patent/WO2015038777A1/en not_active Ceased
- 2014-09-11 SG SG11201601730TA patent/SG11201601730TA/en unknown
- 2014-09-11 WO PCT/US2014/055254 patent/WO2015038818A2/en not_active Ceased
- 2014-09-11 US US14/484,160 patent/US9925263B2/en active Active
- 2014-09-11 JP JP2016542103A patent/JP6469113B2/ja active Active
- 2014-09-11 CN CN201910681927.9A patent/CN110496099B/zh active Active
- 2014-09-11 CA CA2923859A patent/CA2923859C/en active Active
- 2014-09-11 CN CN201480061505.7A patent/CN105722501B/zh active Active
- 2014-09-11 SG SG11201601728YA patent/SG11201601728YA/en unknown
- 2014-09-11 CN CN201480061377.6A patent/CN105705139B/zh active Active
- 2014-09-11 KR KR1020247009336A patent/KR102772684B1/ko active Active
- 2014-09-11 EP EP20205250.2A patent/EP3791862B1/en active Active
- 2014-09-11 AU AU2014318725A patent/AU2014318725B2/en active Active
- 2014-09-11 CN CN201480061504.2A patent/CN105722500B/zh active Active
- 2014-09-11 ES ES14776954T patent/ES2837629T3/es active Active
- 2014-09-11 ES ES14781338T patent/ES2959451T3/es active Active
- 2014-09-11 CA CA2923843A patent/CA2923843C/en active Active
- 2014-09-11 SG SG10201806539XA patent/SG10201806539XA/en unknown
-
2016
- 2016-03-03 IL IL244433A patent/IL244433B/en active IP Right Grant
- 2016-03-03 IL IL244430A patent/IL244430B/en active IP Right Grant
- 2016-03-10 MX MX2021012050A patent/MX2021012050A/es unknown
- 2016-03-10 MX MX2021005907A patent/MX2021005907A/es unknown
- 2016-03-10 MX MX2021012048A patent/MX2021012048A/es unknown
- 2016-03-10 MX MX2021012049A patent/MX2021012049A/es unknown
- 2016-03-22 ZA ZA2016/01968A patent/ZA201601968B/en unknown
-
2017
- 2017-11-10 US US15/809,602 patent/US10821183B2/en active Active
-
2018
- 2018-02-06 US US15/890,044 patent/US10821184B2/en active Active
- 2018-02-23 US US15/903,523 patent/US10646571B2/en active Active
- 2018-02-23 US US15/903,635 patent/US10849977B2/en active Active
- 2018-03-12 ZA ZA2018/01669A patent/ZA201801669B/en unknown
- 2018-04-03 ZA ZA2018/02108A patent/ZA201802108B/en unknown
- 2018-09-28 JP JP2018183794A patent/JP6564512B2/ja active Active
- 2018-12-29 JP JP2018248768A patent/JP6774484B2/ja active Active
-
2019
- 2019-02-25 JP JP2019031843A patent/JP6768858B2/ja active Active
- 2019-06-11 JP JP2019108536A patent/JP6941137B2/ja active Active
- 2019-07-26 JP JP2019137552A patent/JP6840797B2/ja active Active
-
2020
- 2020-03-30 AU AU2020202240A patent/AU2020202240B2/en active Active
- 2020-04-06 AU AU2020202408A patent/AU2020202408B2/en active Active
- 2020-04-06 AU AU2020202407A patent/AU2020202407B2/en active Active
- 2020-10-02 JP JP2020167521A patent/JP7214697B2/ja active Active
- 2020-10-09 US US17/067,058 patent/US11819550B2/en active Active
- 2020-10-19 US US17/073,618 patent/US11986526B2/en active Active
- 2020-11-23 US US17/101,063 patent/US20210085792A1/en not_active Abandoned
-
2021
- 2021-04-30 ZA ZA2021/02906A patent/ZA202102906B/en unknown
-
2022
- 2022-12-15 JP JP2022200135A patent/JP7583455B2/ja active Active
-
2023
- 2023-02-17 AU AU2023200941A patent/AU2023200941A1/en active Pending
- 2023-03-15 ZA ZA2023/03593A patent/ZA202303593B/en unknown
- 2023-09-16 AU AU2023229619A patent/AU2023229619A1/en active Pending
- 2023-10-20 AU AU2023251546A patent/AU2023251546A1/en active Pending
-
2024
- 2024-02-09 US US18/438,199 patent/US20240181063A1/en active Pending
- 2024-04-15 US US18/635,538 patent/US20240285766A1/en active Pending
- 2024-10-25 JP JP2024188410A patent/JP2025010224A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016530321A5 (ja) | イオン性液体を含有する注射用液状タンパク質製剤およびその使用 | |
| JP2016534141A5 (enExample) | ||
| JP2016530318A5 (enExample) | ||
| RU2016113283A (ru) | Жидкие составы белков, содержащие средства для снижения вязкости | |
| JP2019073563A5 (enExample) | ||
| US20180000932A1 (en) | Formulation of aglycosylated therapeutic antibodies | |
| AR110986A2 (es) | Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso | |
| TW201909904A (zh) | 高濃度調配物 | |
| JP2017530196A5 (enExample) | ||
| US9636376B2 (en) | Stable compositions of peptide epoxy ketones | |
| KR20200029636A (ko) | 입자의 동결건조 또는 동결을 위한 중합체 부형제의 용도 | |
| CA2792965A1 (en) | Stable aqueous mia/cd-rap formulations | |
| JP2020520368A5 (enExample) | ||
| CN104623654A (zh) | 壳寡糖的应用及含壳寡糖的疫苗剂 | |
| CN112656939B (zh) | 一种针对血管内皮生长因子的人源化抗体的药物组合物 | |
| Wang et al. | Absorbable microspheres sustaining epirubicin and TLR7 agonist release for transarterial chemo-immuno-embolization in liver tumor | |
| US11957758B2 (en) | Pharmaceutical composition of docetaxel conjugate and preparation method | |
| AU2025200220A1 (en) | Improved lyophilized formulation | |
| US11229702B1 (en) | High concentration formulations of adalimumab | |
| CN105412942A (zh) | 聚乙二醇化的重组产朊假丝酵母尿酸氧化酶冻干注射剂 | |
| CN104840432A (zh) | 一种紫杉烷类长循环纳米粒及其制备方法 | |
| CN103800909B (zh) | 可消除hs15起昙现象的组合物及其在药物制剂中的应用 | |
| Meng et al. | Targeted Reprogramming of Tumor Cells by Digoxin‐Loaded Immunogenic Nanoparticles Enhances Immunity Against Disseminated Tumor Cells | |
| RU2022128012A (ru) | Жидкие составы белков, содержащие средства для снижения вязкости | |
| CN101954065A (zh) | 注射用重组人血管内皮抑制素纳米粒组合物及制备方法 |